APA

Halmos B., Tan E., Soo R. A., Cadranel J., Lee M. K., Foucher P., Hsia T., Hochmair M., Griesinger F., Hida T., Kim E., Melosky B., Märten A. & Carcereny E. (20191227). Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo). : Lung cancer (Amsterdam, Netherlands).

Chicago

Halmos Balazs, Tan Eng-Huat, Soo Ross A, Cadranel Jacques, Lee Min Ki, Foucher Pascal, Hsia Te-Chun, Hochmair Maximilian, Griesinger Frank, Hida Toyoaki, Kim Edward, Melosky Barbara, Märten Angela and Carcereny Enric. 20191227. Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo). : Lung cancer (Amsterdam, Netherlands).

Harvard

Halmos B., Tan E., Soo R. A., Cadranel J., Lee M. K., Foucher P., Hsia T., Hochmair M., Griesinger F., Hida T., Kim E., Melosky B., Märten A. and Carcereny E. (20191227). Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo). : Lung cancer (Amsterdam, Netherlands).

MLA

Halmos Balazs, Tan Eng-Huat, Soo Ross A, Cadranel Jacques, Lee Min Ki, Foucher Pascal, Hsia Te-Chun, Hochmair Maximilian, Griesinger Frank, Hida Toyoaki, Kim Edward, Melosky Barbara, Märten Angela and Carcereny Enric. Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo). : Lung cancer (Amsterdam, Netherlands). 20191227.